
Inari Medical NARI
Quarterly report 2024-Q3
added 10-28-2024
Inari Medical Book Value 2011-2026 | NARI
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Inari Medical
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 417 M | 239 M | 200 M | -39.1 M | -39.4 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 417 M | -39.4 M | 156 M |
Quarterly Book Value Inari Medical
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 435 M | 424 M | 447 M | 465 M | 452 M | 436 M | 427 M | 417 M | 415 M | - | 419 M | 239 M | 234 M | 222 M | 214 M | 200 M | 200 M | 200 M | 200 M | 15 M | 15 M | 15 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 465 M | 15 M | 290 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Align Technology
ALGN
|
3.85 B | $ 174.53 | -1.3 % | $ 13.1 B | ||
|
Alphatec Holdings
ATEC
|
791 M | $ 11.07 | -5.06 % | $ 1.66 B | ||
|
Bio-Rad Laboratories
BIO
|
6.57 B | $ 277.5 | -1.3 % | $ 7.83 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
-879 K | - | -26.83 % | $ 2.62 M | ||
|
AdaptHealth Corp.
AHCO
|
1.53 B | $ 12.22 | 0.33 % | $ 1.65 B | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
EDAP TMS S.A.
EDAP
|
56.9 M | $ 3.36 | -0.3 % | $ 126 M | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
Bruker Corporation
BRKR
|
1.82 B | $ 37.98 | -0.71 % | $ 5.66 K | ||
|
Cytosorbents Corporation
CTSO
|
5.9 M | $ 0.6 | -2.45 % | $ 37.3 M | ||
|
Boston Scientific Corporation
BSX
|
43.7 B | $ 61.28 | -2.05 % | $ 90.7 B | ||
|
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | ||
|
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | ||
|
ClearPoint Neuro
CLPT
|
28 M | $ 8.96 | -2.29 % | $ 254 M | ||
|
Electromed
ELMD
|
43.2 M | $ 24.41 | 0.04 % | $ 206 M | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
Second Sight Medical Products
EYES
|
15.7 M | - | -0.97 % | $ 54.4 M | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
27.7 M | - | 1.37 % | $ 20.5 M | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
GBS
GBS
|
2.81 M | - | -0.57 % | $ 7.12 M | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
Globus Medical
GMED
|
4.57 B | $ 91.4 | -0.61 % | $ 12.4 B | ||
|
Butterfly Network
BFLY
|
169 M | $ 4.15 | 0.24 % | $ 878 M | ||
|
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | ||
|
BIOLASE
BIOL
|
1.96 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
111 M | $ 9.88 | 0.3 % | $ 354 M | ||
|
BioSig Technologies
BSGM
|
133 M | - | 37.08 % | $ 85.7 M | ||
|
Inogen
INGN
|
192 M | $ 6.66 | -0.15 % | $ 177 M | ||
|
Inspire Medical Systems
INSP
|
781 M | $ 56.69 | 6.2 % | $ 1.66 B | ||
|
CONMED Corporation
CNMD
|
1.03 B | $ 36.93 | 0.93 % | $ 1.15 B | ||
|
IRIDEX Corporation
IRIX
|
4.92 M | $ 1.04 | 0.97 % | $ 17.6 M | ||
|
Integer Holdings Corporation
ITGR
|
1.75 B | $ 86.67 | -0.93 % | $ 3.01 B | ||
|
FONAR Corporation
FONR
|
146 M | $ 18.61 | -0.05 % | $ 122 M | ||
|
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
10.3 B | $ 79.15 | -3.13 % | $ 46.3 B | ||
|
OrthoPediatrics Corp.
KIDS
|
347 M | $ 15.94 | -0.44 % | $ 374 M | ||
|
Helius Medical Technologies
HSDT
|
2.35 M | $ 1.89 | 0.53 % | $ 1.15 M | ||
|
LivaNova PLC
LIVN
|
1.2 B | $ 63.37 | -2.0 % | $ 3.46 B | ||
|
LENSAR
LNSR
|
-12.2 M | $ 5.46 | -1.27 % | $ 65.3 M | ||
|
Cutera
CUTR
|
-172 M | - | -10.19 % | $ 1.99 M |